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Characterisation of the cells in repair tissue following autologous 1 
chondrocyte implantation in mankind: a novel report of two cases. 2 
 3 
Abstract 4 
Aims: Autologous chondrocyte implantation (ACI) is used worldwide for the 5 
treatment of cartilage defects. This study has aimed to assess for the first time 6 
those cells that are contained within human ACI repair tissues several years 7 
post-treatment. We have compared the phenotypic properties of cells from within 8 
the ACI repair to adjacent chondrocytes and subchondral bone derived-9 
mesenchymal stem cells (MSC). 10 
Materials and methods: Two patients undergoing arthroplasty of their ACI-11 
treated joint were investigated. Tissue and cells were isolated from the repair 12 
site, adjacent macroscopically normal cartilage and MSC from the subchondral 13 
bone and characterised for their growth kinetics, morphology, immunoprofile and 14 
differentiation capacity. 15 
Results: ACI repair tissue appeared fibrocartilaginous and ACI repair cells were 16 
heterogeneous in morphology and size when freshly isolated, becoming more 17 
homogeneous, resembling chondrocytes from adjacent cartilage, after culture 18 
expansion. The same weight of ACI repair tissue resulted in less cells than 19 
macroscopically normal cartilage. During expansion ACI repair cells proliferated 20 
faster than MSC but slower than chondrocytes. ACI repair cell immunoprofiles 21 
resembled chondrocytes, but their differentiation capacity matched MSC. 22 
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Conclusion: This novel report demonstrates that human ACI repair cell 23 
phenotypes resemble both chondrocytes and MSC but at different stages of their 24 
isolation and expansion in vitro. 25 
Keywords: Autologous chondrocyte implantation; histochemical analysis; repair 26 
cell characterisation, phenotype, morphology, growth kinetics, immunoprofile, 27 
differentiation potential. 28 
29 
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Introduction 30 
There is a huge interest worldwide in the development of tissue engineering and 31 
cell based therapies for the treatment of cartilage defects. Autologous 32 
chondrocyte implantation (ACI) is a procedure that has been used for more than 33 
20 years for the treatment of cartilage injury and osteoarthritis[1-3]. Our centre 34 
has provided cells for over 400 ACI procedures since its inception, of which 81% 35 
were a success, as indicated by a postoperative increase in Lysholm score[4]. 36 
What happens to the culture expanded chondrocytes after implantation and the 37 
contribution that they make to the repair tissue compared to cells from 38 
surrounding tissues is still largely unknown[5-7]. Few preclinical studies have 39 
labelled and tracked transplanted chondrocytes in ACI models. Those that have, 40 
show that varying proportions of the cells injected form the cellular component of 41 
the tissue at the site of ACI. In these studies transplanted cells have been shown 42 
to contribute in part to the formation and integration of repair tissues. However, 43 
numerous unlabelled cells also form a major constituent, which suggests that 44 
cells of unknown origin migrate to ACI-treated lesions and combine with 45 
transplanted cells as part of the healing process[6-7]. 46 
 The purpose of this study is to describe for the first time the phenotype of 47 
those cells that are contained within the tissue at the site of ACI in humans 48 
several years after treatment. Characterisation of the cells that are present at the 49 
site of ACI and hence, that are likely to produce and remodel the repair tissue, is 50 
critical to our understanding of the biological process in ACI. In previous studies 51 
we have only been able to assess the quality of ACI repair tissues in the clinic via 52 
magnetic resonance imaging (MRI) and histological analyses of small regions 53 
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(<1mm diameter cores)[8-11]. We have obtained two rare samples which have 54 
provided us with the opportunity to isolate and examine the behaviour and 55 
phenotypic properties of ACI repair cells in culture, in comparison to both 56 
chondrocytes in the adjacent cartilage and MSC from the subchondral bone. 57 
Observing ACI repair cells in culture will help to provide novel information on the 58 
cellular component of ACI repair tissues which we can then compare to 59 
histological analyses and clinical outcome. In addition, by analysing the 60 
properties of ACI repair cells in contrast to the phenotypes of cells isolated from 61 
neighbouring tissues (e.g. cartilage and bone) we may begin to elucidate ACI 62 
repair cell origin. Herein we describe the analysis of repair tissues and cells from 63 
two former ACI patients that have returned to our clinic for arthroplasty of their 64 
ACI-treated joints several years post-ACI. 65 
66 
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Materials and methods 67 
Patient information 68 
Following Local Research Ethical Committee approval and with informed 69 
consent, tissues obtained from two patients undergoing joint replacement surgery 70 
were included in this study (one knee – Patient 1 and one hip – Patient 2). Both 71 
were males aged 49 and 44 years at the time of arthroplasty, which was 11 and 5 72 
years, respectively, after previous ACI treatment (Table 1).  73 
Histological analysis 74 
For histological examination decalcified wax-embedded tissue sections from the 75 
region bridging macroscopically normal cartilage (MNC) and ACI repair tissues 76 
(with subchondral bone) from Patients 1 and 2 were examined using 77 
haematoxylin and eosin (H&E) and toluidine blue stains as described 78 
previously12. For H&E histological examination, sections were flooded with 79 
Mayer’s haemalum (VWR International Ltd, Poole, UK) for 1 minute, drained, and 80 
washed in tap water for 5 minutes. Slides were then flooded with 1% eosin 81 
aqueous solution (BDH, Poole, UK) (in distilled water) for 30 seconds, briefly 82 
washed in tap water and dehydrated through a series of isopropanol (Genta 83 
Medical, York, UK) concentrations in distilled water and xylene, for 5 minutes 84 
each. Following dehydration, the tissue sections were mounted under glass 85 
coverslips (Cell Path Ltd, Newtown, UK) with Pertex mounting medium (Histolab 86 
Products AB, Gothenburg, Sweden) and allowed to air dry.  Glycosaminoglycan 87 
(GAG) content was assessed by metachromasia by flooding sections with 1% 88 
aqueous toluidine blue (BDH) solution for 30 seconds and rinsed in tap water.  89 
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Slides were left to air dry before mounting under glass coverslips with Pertex 90 
mounting medium. 91 
 For collagen type II immunolocalisation, dewaxed and rehydrated sections 92 
were pre-treated with 0.1% (w/v) hyaluronidase and 0.2% (w/v) trypsin (Sigma-93 
Aldrich, Poole, UK) for 1 hour at 370C. Sections were then washed in phosphate 94 
buffered saline (PBS) and incubated for 2 hours at room temperature in a 95 
humidified chamber with 10µg/ml of primary mouse monoclonal collagen type II 96 
antibody (clone CIIC1, Developmental Studies Hybridoma Bank, University of 97 
Iowa) in PBS. Parallel sections were incubated with a non-specific, isotype-98 
matched antibody (IgG1- Dako, Glostrup, Denmark) instead of the primary 99 
antibody at the same concentration as a negative control. After incubation with 100 
the primary antibodies all sections were washed in PBS before incubation for 1 101 
hour with a secondary biotinylated antibody at 50µg/ml (Vector ABC System, 102 
Vector Laboratories, Peterborough, UK) according to manufacturers instructions. 103 
To eliminate endogenous peroxidase activity sections were blocked with 3% (v/v) 104 
hydrogen peroxide (H2O2) in methanol (BDH) for 30 minutes. Collagen type II 105 
immunopositivity was finally visualised by testing for bound peroxidise, which is 106 
detected by incubation with a substrate of diaminobenzidine tetrahydrochloride 107 
(DAB), activated by H2O2. The sections were then dehydrated before mounting 108 
under glass coverslips with Pertex mounting medium as described previously. 109 
Chondrocyte and ACI repair cell isolation and culture 110 
Approximately 300mg of MNC and ACI repair tissues were harvested from the 111 
medial femoral condyle (MFC) of Patient 1 and the femoral head (FH) of Patient 112 
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2. Cells were isolated and cultured as described previously for chondrocytes[13]. 113 
MNC and ACI repair tissues were dissected into ~2mm3 pieces and placed into 114 
25cm2 tissue culture flasks (Falcon 250 ml Polystyrene Tissue Culture Flask, BD 115 
Biosciences, UK). The weight of each tissue type was recorded and cells 116 
released by enzymic digestion. Dulbecco’s Modified Eagle’s Medium 117 
(DMEM)/F12 (Life Technologies, Paisley, UK) containing 0.8mg/ml type XI 118 
collagenase (Sigma-Aldrich) was added to each of the flasks which were then 119 
incubated at 5% (v/v) CO2 for 20 hours at 37oC. 120 
 Following this incubation, each tissue digest was passed through a 70µm 121 
cell strainer (BD Biosciences); cells were recovered by centrifugation at 750g for 122 
10 minutes to form a cell pellet. Cells were plated out in DMEM/F12, 123 
supplemented with 10% foetal bovine serum (FBS) (Life Technologies), 50µg/ml 124 
ascorbic acid (AA; Sigma-Aldrich) and 1% (v/v) penicillin and streptomycin (P/S; 125 
Life Technologies) at a seeding density of 5 x 105 cells per cm2. After 5 days, 126 
non-adherent cells were removed and the adherent cell population was cultured 127 
in monolayer in DMEM/F12 10% FBS medium supplemented with AA and P/S. 128 
Cells were routinely passaged at 70% confluence by trypsinisation (0.05% v/v 129 
Trypsin-EDTA) and re-seeded at 5 x 103 cells/ cm2.  130 
Human bone marrow stem cell (MSC) isolation and culture  131 
The underlying bone from the MFC of Patient 1 and the FH of Patient 2 was 132 
perfused with DMEM/F12 (Life Technologies) supplemented with 10% FBS and 133 
P/S. Mononuclear cells isolated and MSC cultured as described previously[14]. 134 
Mononuclear cells isolated by density gradient centrifugation (Lymphoprep, 135 
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Fresenius Kabi Norge, AS) were plated out in DMEM/F12, supplemented with 136 
20% FBS and P/S at a seeding density of 20 x 106 cells per 25cm2 tissue culture 137 
flask. After 24 hours, non-adherent cells were removed and the adherent cell 138 
population was cultured in monolayer in DMEM/F12 10% FBS medium 139 
supplemented with P/S. Cells were routinely passaged at 70% confluence by 140 
trypsinisation (0.05% v/v Trypsin-EDTA) and re-seeded at 5 x 103 cells/ cm2. 141 
Viability was assessed at each passage by trypan blue exclusion (Sigma-142 
Aldrich). 143 
Microscopy, image capture and analysis   144 
Histological sections were viewed using bright light and polarized light 145 
microscopy (Leitz Diaplan, Wetzlar, Germany) and digitized images were 146 
captured with a Nikon digital camera (DS-Fi1, Nikon, Kingston-upon-Thames, 147 
UK). Cultures were viewed using phase contrast microscopy (Nikon Eclipse 148 
TS100) and digitized images were captured with a Hamamatsu digital camera 149 
(C4742-95, Bridgewater, NJ). The mean cell area was determined from passage 150 
0-3 for the three cell populations using IPLab software (Version 3.6, Nikon). For 151 
each cell type, results from at least 5 separate images per culture were 152 
combined. 153 
Growth kinetics 154 
Culture doubling time was calculated for each cell population (from passage 0-3) 155 
using the following formula: doubling time (DT) = (t2-t1) x ln(2)/ ln(n2/n1), where 156 
t1 = the time of cell seeding, t2 = the time of cell harvest and n = the matching 157 
cell numbers at these time points. 158 
Immunoprofiling 159 
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Immunoprofiling via flow cytometry was used to assess culture expanded cells (at 160 
passage 2) using a FACScan flow cytometer (BD Biosciences). A profile typical 161 
of MSC was targeted [15]. In brief, cells were blocked for one hour in a buffer of 162 
10% normal human Ig (Grifols, Cambridge, UK). Cells were then incubated with 163 
mouse anti-human monoclonal primary antibodies against CD14, CD19, CD31, 164 
CD34, CD45, CD73, CD90, CD105 and HLA-DR (all phycoerythrin-conjugated) 165 
(Immunotools, Friesoythe, Germany) for 30 minutes. Matched cell populations 166 
were also exposed to isotype-matched IgG negative control antibodies (Sigma-167 
Aldrich). Immunoprofiles were produced using Cell Quest software (BD 168 
Biosciences). 169 
Multipotency assays 170 
Established protocols [16-18] were used to assay the differentiation potential of 171 
cells at passage 2 for adipogenic, osteoblastic and chondrogenic lineages. In 172 
brief, for 21 days, cell cultures were exposed to appropriate conditions for: (i) 173 
adipogenic differentiation via monolayer culture in DMEM/F12 10% FCS, 1% ITS-174 
X (Life Technologies), dexamethasone, 3-isobutyl-1-methylxanthine and 175 
indomethacin (Sigma-Aldrich); (ii) osteoblastic differentiation via monolayer 176 
culture in DMEM/F12 10% FCS, ascorbate 2-phosphate, dexamethasone and β-177 
glycerophosphate (Sigma-Aldrich); (iii) chondrogenic differentiation via micro-178 
mass pellet culture in DMEM/F12, 1% ITS-X, ascorbate 2-phosphate (Sigma-179 
Aldrich), dexamethasone (Sigma-Aldrich) and TGF-β1 (PeproTech Ltd., London, 180 
UK).  181 
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At the 21 day time point, adipogenic differentiation potential was examined 182 
via oil red-O visualisation of lipid formation, alkaline phosphatase activity was 183 
used to assess osteoblast differentiation and for chondrogenic differentiation, 184 
toluidine blue staining was used to detect the presence of GAGs in micro-mass 185 
pellets. 186 
Statistical analysis  187 
The Kruskal-Wallis non-parametric ANOVA and post-hoc Bonferroni pair-wise 188 
comparison tests were used to assess significant differences between the size 189 
(area coverage) of each cell type isolated from the same joint e.g. Chondrocytes, 190 
ACI repair cells and MSC between passages 0-3. 191 
192 
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Results 193 
Histological analysis 194 
Tissue sections from the region bridging MNC and ACI repair tissues (Figure 1A) 195 
were examined via H&E staining (Figure 1B) which demonstrated a disorganized 196 
cellular distribution throughout ACI repair tissues in both patients compared to 197 
neighbouring MNC. There appeared to be good integration between the repair 198 
cartilage and the neighbouring MNC and the underlying bone. The surface 199 
integrity and smoothness of ACI repair tissues differed between patients; in the 200 
knee (patient 1) the repair surface was rough, whereas the hip repair tissue 201 
(patient 2) was smooth but undulating compared to neighbouring MNC which was 202 
smooth and flat in both patients. 203 
 Viewing the same section under polarized light (Figure 1C) revealed  204 
illuminated areas of scattered light indicative of fibrocartilage throughout the 205 
repair region and in particular at the border with MNC. Toluidine blue staining 206 
(Figure 1D) indicated that the GAG content of ACI repair tissues was lower than 207 
that in neighbouring MNC, particularly in the surface zone. For both patients 208 
collagen type II staining (Figure 1E) was similarly weaker in the surface zone of 209 
ACI repair tissues. 210 
Morphological analyses 211 
For both patients freshly isolated chondrocytes and MSC had a uniform 212 
fibroblast-like morphology with their size (surface area coverage) increasing after 213 
expansion. MSC appeared consistently larger at each passage compared to 214 
chondrocytes. In addition, for MSC cultures numerous intracellular stress fibres 215 
were clearly visible at passage 3. In contrast, the morphologies of freshly isolated 216 
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ACI repair cells were more heterogeneous. ACI repair cells possessed a 217 
combination of early and later passage chondrocyte and MSC-like morphologies 218 
after initial seeding but became homogeneous after sub-culture. There were no 219 
obvious or significant differences between ACI and chondrocyte cultures (Figures 220 
2A and 2B).  221 
Growth kinetics 222 
Chondrocytes and ACI repair cells proliferated at similar rates for both patients 223 
(from passages 0-3), with DTs of 2 weeks between passages 0-1, decreasing to 224 
4-6 days between passages 1-2 and 2-3.  In contrast, the DT of MSC was 225 
markedly higher at 8-14 days between passages 1-2 and 2-3 (Figure 3A). At 226 
passage 3 chondrocyte cultures produced harvests of 1.4x108, ACI repair cells 227 
4.3x107 and MSC 9.0x106 (Figure 3B). Viability for all cells was >98% at each 228 
passage. 229 
Immunoprofiles 230 
MSC from both patients’ were CD14, CD19, CD31, CD34, CD45 and HLA-DR 231 
negative and CD73, CD90 and CD105 positive; this matches previously 232 
published MSC immunoprofiles15. Chondrocytes and ACI repair cells from both 233 
patients had MSC-like immunoprofiles apart from some positivity for CD14; for 234 
patient 1 CD14 was detected on ~90% of chondrocytes and ~50% of ACI repair 235 
cells, whereas for patient 2 the reverse pattern of positivity was observed 236 
between chondrocytes (~50% immunopositive) and ACI (~90% immunopositive) 237 
(Figure 4). 238 
Differentiation potential 239 
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Chondrocytes, ACI repair cells and MSC from both patients differentiated along 240 
all three mesenchymal cell lineages tested but to varying degrees, as delineated 241 
by lipid accumulation, alkaline phosphatase activity and toluidine blue GAG 242 
staining. Chondrocytes from patient 1 produced a large frequency of clustered 243 
globular lipids, whereas chondrocytes from patient 2 showed more diffuse 244 
staining of smaller lipids throughout. ACI and MSC staining for lipid accumulation 245 
was similar in pattern for both patients, hence, a few unilocular lipid clusters 246 
(which may be indicative of committed adipocytes) were seen in both (Figure 5A). 247 
Chondrocytes from both patients showed intense uniform staining for alkaline 248 
phosphatase activity, whereas ACI repair cells and MSC demonstrated a more 249 
heterogeneous pattern of staining (Figure 5B). All pellet cultures showed the 250 
presence of some GAGs via toluidine blue staining. Chondrocyte fractions 251 
showed the most intense toluidine blue staining, ACI repair cell and MSC pellets 252 
showed weaker GAG staining for both patients (Figure 5C). 253 
254 
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Discussion 255 
These samples have provided a unique opportunity to study both the histology of 256 
the complete area of ACI repair tissue compared to neighbouring MNC as well as 257 
examining the phenotype of ACI repair cells compared to chondrocytes from 258 
adjacent cartilage and MSC from the underlying subchondral bone, several years 259 
post-ACI. For these analyses, tissues and cells were harvested from two former 260 
ACI patients at the time of arthroplasty. It is debatable whether the patients 261 
included in this study and hence, the tissues and cells examined here should be 262 
considered as ACI successes or failures. These individuals were 38 and 39 years 263 
of age at the time that they received ACI and although their treated joints 264 
ultimately failed, ACI prolonged the life of their natural joints for 11 and 5 years, 265 
respectively. For patients of such a young age this may have important 266 
implications for later life as joint replacement is accompanied by some loss of 267 
function which restricts activities[19]. In addition, joint replacements will probably 268 
not last for the full life of younger patients. Hence, the initial surgery may need 269 
revision which is a more complicated and expensive operation with lower 270 
success rates than primary arthroplasty[20]. As such, ACI therapy which 271 
increases the life-span of these young patients’ joints may understandably be 272 
considered a successful intervention even though their treated joints eventually 273 
failed. 274 
 Histologically, we have shown that ACI repair tissues resembled those 275 
previously described[8-10]; cells were numerous but disorganised and matrices 276 
appeared predominantly fibrocartilaginous. Repair tissues were well integrated 277 
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with adjacent MNC and subchondral bone. The surface of repair tissue for patient 278 
1 was rough compared to that of patient 2, perhaps because patient 1 received a 279 
periosteal graft, which may exhibit hypertrophy, compared to the collagen 280 
membrane which was used for patient 2[21]. There were no obvious histological 281 
signs that may have explained joint failure in these patients. However, there is 282 
limited evidence that histology is a reliable indicator of clinical outcome for ACI 283 
patients[22]. In this study we have some preliminary data for ACI repair cell 284 
characterisation, which may represent a promising additional prognostic marker 285 
in future analyses. An understanding of the ACI repair cell phenotype will help to 286 
elucidate ACI repair tissue formation and remodelling processes. In addition, we 287 
may be able to use this data to begin to ‘unpick’ the origin of ACI repair cells and 288 
hence, to determine if ACI tissues contain any of those cells initially implanted at 289 
ACI stage II. In preclinical studies transplanted cells are known to persist in ACI 290 
repair zones for up to 14 weeks in large animal models[6]. Alternatively, the site 291 
of ACI repair may contain a completely different cell type (e.g. synovium, bone, or 292 
bone marrow-derived MSC) that have migrated and integrated into ACI zones 293 
from surrounding tissues[23-25]. 294 
 It is likely that the anatomical location (i.e. knee versus hip) and the patch 295 
used at ACI (i.e. periosteum versus Chondro-Gide®) will have influenced the 296 
quality and extent of the repair tissue observed for Patient 1 compared to Patient 297 
2. However, there were no discernible differences observed in the phenotypes of 298 
ACI repair cells isolated from Patient 1 or Patient 2. This suggests that the 299 
dissimilarities between these examples of ACI i.e. the type of joint treated and 300 
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patch used might not have contributed significantly to the tissue regeneration 301 
seen (or the cells involved) in these ACI treated joints. We have shown that 302 
freshly isolated cells from ACI repair tissues appeared to contain a mixture of 303 
chondrocyte and MSC morphologies, but that MSC-like cells disappear over time 304 
in culture. Our growth kinetics data supports the theory that chondrocytes may 305 
have outgrown MSC in vitro. In addition, the immunoprofiles of chondrocytes and 306 
ACI repair cells were similar after sub-culture, both demonstrated some CD14 307 
positivity, a marker found on freshly isolated chondrocytes[26,27] compared to a 308 
complete absence of CD14 on MSC at the same passage. It is unlikely that the 309 
source of CD14 positive cells that were cultured from ACI repair tissues 310 
represent MSC which have migrated from surrounding tissues e.g. MSC from 311 
synovium and bone or bone marrow as these MSC do not express CD14 in an 312 
undifferentiated state[15,28]. It is conceivable that these cells instead either 313 
represent a proportion of the chondrocytes that were originally transplanted at 314 
ACI or that have migrated from adjacent cartilage. Alternatively, an MSC 315 
population may have homed to the injured region and differentiated in vivo 316 
towards a chondrogenic lineage[29,30]. 317 
 Interestingly, our multipotency studies showed a marked contrast between 318 
passaged chondrocyte and ACI repair cell differentiation potential. Chondrocyte 319 
populations differentiated along adipogenic, osteogenic and chondrogenic 320 
lineages in a strongly positive and uniform manner as articular cartilage itself 321 
contains a multipotent progenitor cell population [31-35]. In contrast, ACI repair 322 
cells appeared heterogeneous and on the whole, differentiated along each 323 
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mesenchymal lineage tested to a lesser extent, akin to MSC isolated from the 324 
same joint. However, we acknowledge that culture expansion may change the 325 
characteristics of ACI repair cells. It is therefore difficult to ascertain exactly how 326 
the immunoprofile and differentiation potential of culture-expanded ACI repair 327 
cells relate to their in vivo characteristics. None the less, this study demonstrates 328 
that although cultured ACI repair cells possess many phenotypic characeristics of 329 
chondrocytes e.g. similar morphologies, growth kinetics and immunoprofiles, they 330 
do not possess the ability to differentiate, importantly in this setting, into 331 
chondrocytes with physiologically relevant properties. For example, ACI repair 332 
cells do not appear to synthesise GAG rich matrices to the same extent as 333 
chondrocytes when chondrogenically induced in vitro. This finding coincides with 334 
our in vivo histological evidence which clearly shows that ACI repair tissues 335 
possess a lower GAG content in comparison to neighbouring MNC.  336 
A limitation of this study is that it is based on only two human samples, 337 
making the findings a little difficult to interpret. We hope to expand and 338 
corroborate the findings of these pilot experiments by increasing the sample size 339 
of donors and expanding the molecules and markers to be investigated in longer 340 
term studies. For example, immunohistochemical analyses to determine the 341 
presence of type X collagen as a marker of hypertrophy in repair tissues and 342 
gene expression studies of isolated repair cells for osteogenic and chondrogenic 343 
associated molecules using RT-qPCR would provide valuable additional data. 344 
Nonetheless, this pilot study has provided a rare opportunity to carry out studies 345 
which are normally only possible in animals, but even then at much shorter time 346 
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points. The information obtained is therefore completely novel and likely to be 347 
more relevant to the human patient than results from animal studies. 348 
349 
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Conclusions 350 
This study presents the first data on human ACI repair cell phenotypes in culture, 351 
several years after ACI treatment. Cells isolated from ACI repair tissue appeared 352 
to contain a mixture of chondrocytes and MSC morphologies at initial seeding, 353 
but became more like chondrocytes with regard to morphology, proliferation and 354 
immunoprofile at later passage. However, the differentiation potential of 355 
expanded ACI repair cells was reduced for each mesenchymal lineage tested 356 
compared to chondrocytes and notably so for chondrogenic potential which is 357 
considerably relevant in this setting. These findings indicate that ACI repair cells 358 
are composed of a mixture of cells with features resembling both chondrocyte 359 
and MSC phenotypes. This suggests that ACI tissues contain both chondrocytes 360 
(either originally implanted or integrated from surrounding cartilage in vivo) and 361 
also MSC that have infiltrated the treated region from synovium or subchondral 362 
bone. A better understanding of the source of cells which contribute to the repair 363 
tissue in ACI, especially when associated with the best clinical outcome, will 364 
provide valuable information to help improve the ACI technique in the clinic. For 365 
example, we may be able to select the most effective cells prior to implantation or 366 
to augment the migration of desirable endogenous cells from the nearby tissues. 367 
In this way we can make step changes and improvements in current cell therapy 368 
treatments of chondral defects. 369 
370 
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Summary Points 371 
Patient Information  372 
• We have analysed tissues and cells isolated from regions of repair in two 373 
patients undergoing arthroplasty several years after cell therapy with 374 
autologous chondrocytes; these have been compared to tissues and cells 375 
derived from adjacent cartilage and bone. 376 
Histological analysis  377 
• ACI repair tissues were densely populated with cells but the extracellular 378 
matrix was disorganised and contained little GAG or collagen type II in 379 
surface zones compared to adjacent, macroscopically normal cartilage. 380 
Morphological analyses  381 
• Cells which were isolated freshly from ACI repair tissues had a mixture of 382 
chondrocyte and MSC-like morphologies. 383 
Growth kinetics, Immunoprofiles and Differentiation potential  384 
• Following culture expansion, cells isolated from ACI repair tissues 385 
resembled chondrocytes in terms of their growth and immunoprofile but 386 
their adipogenic, osteogenic and (importantly) chondrogenic differentiation 387 
capacity was markedly reduced in comparison to chondrocytes isolated 388 
from adjacent macroscopically normal cartilage. 389 
390 
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Figure Legends 512 
Figure 1.  Histology of the ACI: adjacent macroscopically normal cartilage (MNC) 513 
interface. Dotted line shows the ACI treated areas. A, Samples received following 514 
arthroplasty, showing ACI repair regions at the centre of the medial condyle 515 
(patient 1, top) and femoral head (patient 2, bottom). Regions dissected for 516 
histology are indicated (boxed). B, Haematoxylin and eosin stained sections 517 
showing a disorganized cell distribution in ACI repair tissues (left) compared to 518 
typical hyaline cartilage cell organization (right). C, Polarized light illumination 519 
showing fibrocartilage (bright scatter) in ACI repair tissues (left), particularly 520 
evident at ACI: MNC interfaces (centre). D, Toluidine blue localization of GAGs 521 
demonstrates that there are fewer GAGs present in ACI repair regions (left) 522 
compared to MNC (right). A dramatic reduction in GAG staining intensity is seen 523 
in the surface zone of ACI repair tissues. E, Collagen type II immunolocalization 524 
demonstrates that ACI repair region matrices (left) contain less collagen type II 525 
compared to MNC (right). All calibration bars = 1mm. 526 
Figure 2. Cell characterisation: Morphology. A, Freshly isolated cells are shown 527 
(top panels) compared to cells at passage 3 (bottom panels). Chondrocytes (C) 528 
and mesenchymal stromal cells (MSC) isolated from both patients have a uniform 529 
fibroblast-like morphology which increase in size (area coverage) with sub-530 
culture. Freshly isolated ACI repair cells (ACI) show a heterogeneous 531 
morphology which becomes homogeneous at passage 3. All calibration bars = 532 
200µm. B, Chondrocytes (black bars) and MSC (white bars) increase in size from 533 
passages 0-3. Chondrocytes are significantly smaller than MSC at every passage 534 
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quantified. At initial seeding ACI repair cells (grey bars) are significantly larger 535 
than chondrocytes, but similar in size to MSC. At passage 3 ACI repair cells are 536 
significantly smaller than MSC, but similar in size to chondrocytes (means +/- 537 
SEM Kruskal-Wallis ANOVA and post-hoc Bonferroni ***p <0.001).  538 
Figure 3. Cell characterisation: Growth kinetics. A, The doubling times (DT) of 539 
chondrocytes and ACI repair cells decrease similarly through passages 0-3. In 540 
contrast, MSC DT increase between passages 1-3 (means +/- SEM from pooled 541 
patient data). B, After harvest at passage 3 chondrocyte cultures produced 542 
1.4X108 cells, ACI repair cultures 4.3X107 cells and MSC cultures 9.0X106 cells 543 
(means +/- SEM from pooled patient data).  544 
Figure 4. Phenotypic characterisation: Immunoprofile and differentiation capacity 545 
(passage 2 cells). A, Flow cytometry analysis for CD-immunolabelling of 546 
chondrocytes, ACI repair cells and MSC. All cultures tested are CD19-ve, CD31-547 
ve, CD34-ve, CD45-ve, CD73+ve, CD90+ve, CD105+ve and HLA-DR-ve at 548 
passage 2. C and ACI repair cells are also immunopositive for CD14 to varying 549 
degrees (patient 1 chondrocytes are ~50%+ve and ACI are ~90%+ve, patient 2 550 
chondrocytes are ~90%+ve and ACI are ~50%+ve), where as MSC are CD14-ve. 551 
The green-lined histogram denotes immunopositivity (fluorescence intensity) for 552 
each indicated marker, whilst the purple histogram denotes immunolabelling with 553 
an isotype-matched control antibody.  554 
Figure 5. Phenotypic characterisation: Differentiation capacity (passage 2 cells). 555 
A, The presence of lipid vesicles is increased in chondrocytes treated with 556 
adipogenic stimuli (but a different type of staining pattern between patients can 557 
be observed, as revealed with oil red-O), compared with ACI repair cells or MSC 558 
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(which had similar localised unilocular lipid staining in patches). B, Alkaline 559 
phosphatase activity is markedly increased in chondrocyte cultures treated with 560 
osteogenic stimuli compared with ACI repair cells or MSC. C, Toluidine blue 561 
staining of chondrogenically induced pellet cultures shows more intense staining 562 
in chondrocyte pellets compared to ACI repair cell or MSC pellets. Calibration 563 
bars = 100µm, inset calibration bar = 200µm. 564 
Table 1. Patient information: Demographics and ACI treatment received. 565 
  Patient 1 Patient 2 
Time since ACI 135 months 
(~11 years) 
59 months 
(~5 years) 
Site of ACI Medial Femoral Condyle Lateral aspect of  
Femoral Head 
Size of defect 25 x 15mm 12 mm diameter 
Cells received Knee chondrocytes Hip chondrocytes 
Patch received Periosteum Chondro-Gide® 
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